Natixis Advisors LLC Has $14.48 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Natixis Advisors LLC lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 78,439 shares of the medical research company's stock after selling 5,704 shares during the quarter. Natixis Advisors LLC owned approximately 0.15% of Charles River Laboratories International worth $14,480,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CRL. CIBC Asset Management Inc increased its position in Charles River Laboratories International by 8.6% during the third quarter. CIBC Asset Management Inc now owns 7,531 shares of the medical research company's stock worth $1,483,000 after buying an additional 595 shares during the last quarter. Swiss National Bank increased its position in Charles River Laboratories International by 0.5% during the third quarter. Swiss National Bank now owns 152,800 shares of the medical research company's stock worth $30,097,000 after buying an additional 700 shares during the last quarter. Premier Fund Managers Ltd increased its position in Charles River Laboratories International by 56.3% during the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock worth $49,573,000 after buying an additional 90,000 shares during the last quarter. Prospera Private Wealth LLC acquired a new position in Charles River Laboratories International during the third quarter worth approximately $168,000. Finally, Hilton Capital Management LLC increased its position in Charles River Laboratories International by 17.4% during the third quarter. Hilton Capital Management LLC now owns 7,658 shares of the medical research company's stock worth $1,508,000 after buying an additional 1,135 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Bank of America lowered their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Robert W. Baird reduced their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Morgan Stanley reduced their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average target price of $189.77.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $1.94 during trading on Friday, hitting $167.29. The company had a trading volume of 1,638,932 shares, compared to its average volume of 725,184. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a market capitalization of $8.55 billion, a P/E ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The stock's 50-day moving average price is $166.11 and its 200 day moving average price is $183.71. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $273.57.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the previous year, the company posted $2.46 earnings per share. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).